Phospho-TAL1 (Ser122) Antibody

What is TAL1 and what role does its phosphorylation play in hematopoiesis?

TAL1 (also known as SCL) is a hematopoietic-specific transcription factor with crucial functions in blood cell development. It acts as an oncogene when dysregulated, particularly in T-cell acute lymphoblastic leukemia (T-ALL). Phosphorylation of TAL1 at specific residues serves as a key regulatory mechanism controlling its interactions with transcriptional coactivators and corepressors. The precise timing and level of TAL1 expression orchestrate differentiation into specialized blood cells, with phosphorylation events fine-tuning these processes. Specifically, phosphorylation can alter TAL1's ability to interact with other proteins like LSD1 (lysine-specific demethylase 1), affecting its repressive functions in both normal and malignant hematopoiesis .

Which phosphorylation sites on TAL1 have been identified and characterized?

Research has identified and characterized several phosphorylation sites on TAL1, with the most extensively studied being:

• Serine 172 (Ser172): Phosphorylated by Protein Kinase A (PKA) both in vitro and in vivo. This phosphorylation specifically destabilizes TAL1's interaction with LSD1, leading to promoter H3K4 hypermethylation and activation of target genes that are normally suppressed in hematopoiesis .

• Threonine 90 (Thr90): Phosphorylated by Akt (protein kinase B) within TAL1's transactivation domain. This phosphorylation decreases the repressor activity of TAL1 on specific promoters, such as the EpB42 (P4.2) promoter .

Each phosphorylation site appears to regulate distinct aspects of TAL1 function, providing multiple layers of control over this critical transcription factor.

What are the primary methods for detecting phosphorylated TAL1 in research samples?

Several methodological approaches can be employed to detect phosphorylated TAL1 in research samples:

• Western blotting with phospho-specific antibodies: This is demonstrated in the literature where anti-phospho-Akt substrate antibodies were used to detect phosphorylated TAL1 .

• In vitro phosphorylation assays: Using purified proteins (like GST-TAL1 fusion proteins) with specific kinases (PKA, Akt) to demonstrate phosphorylation events, followed by detection methods such as radioisotope labeling or phospho-specific antibodies .

• Immunoprecipitation followed by phospho-detection: As shown in studies where TAL1 was precipitated with antibodies and then blotted with phospho-specific antibodies or general phospho-detection methods .

• Mass spectrometry: For unbiased identification and quantification of phosphorylation sites, though this approach isn't explicitly mentioned in the provided search results.

How should researchers design experiments to distinguish between different TAL1 isoforms and their phosphorylation patterns?

When designing experiments to distinguish between TAL1 isoforms and their phosphorylation patterns, researchers should consider:

• Isoform-specific primers and antibodies: TAL1 exists in two primary isoforms (short and long) generated through alternative promoter usage and splicing. Researchers should design primers that can specifically detect transcripts from different promoters (1-4 for both isoforms, with promoter 5 being specific to TAL1-short) .

• Phosphorylation site mutants: Creating point mutations at key phosphorylation sites (e.g., S172A for Ser172) to assess functional consequences, as demonstrated in studies where these mutations enhanced interaction with LSD1 and inhibited erythroid differentiation .

• Comprehensive protein detection: Since mRNA levels of TAL1 transcripts don't always match protein amounts of the isoforms, researchers should employ protein-level detection methods alongside transcriptional analysis .

• Cell-specific considerations: Different cell lines show varying TAL1 isoform expression patterns. For example, in Jurkat cells, TAL1-long is dominant, while in other contexts, the ratio may differ. These differences should inform experimental design and interpretation .

• Chromatin immunoprecipitation (ChIP): To assess how phosphorylation affects DNA binding and target gene regulation, as studies have shown that TAL1-short binds more strongly to E-protein partners and functions as a more potent transcription factor .

What controls are essential when evaluating TAL1 phosphorylation in experimental settings?

Essential controls for TAL1 phosphorylation experiments include:

• Phosphorylation site mutants: Using TAL1 constructs with mutations at the phosphorylation site of interest (e.g., S172A for Ser172 or T90A for Thr90) to confirm specificity of phosphorylation events and antibody detection .

• Kinase inhibition/activation: Treating cells with specific kinase activators or inhibitors (e.g., PKA inhibitors for Ser172 studies) to demonstrate the specific kinase responsible for the phosphorylation event .

• Phosphatase treatment: Including samples treated with phosphatases to demonstrate that the detected signal is indeed due to phosphorylation.

• Isoform controls: When studying isoform-specific effects, including expression controls for both TAL1-short and TAL1-long to ensure comparable expression levels, as demonstrated in studies measuring total mRNA amount of targets after silencing endogenous TAL1 and expressing specific isoforms .

• Domain deletion controls: Using constructs with deletions of interaction domains (e.g., TAL1 Δ142-185 for LSD1 interaction studies) to confirm functional relationships between phosphorylation and protein-protein interactions .

How does phosphorylation of TAL1 at Ser172 affect its interaction with LSD1 and subsequent gene regulation?

Phosphorylation of TAL1 at Ser172 by PKA significantly impacts its interaction with LSD1 and gene regulation in several ways:

• Destabilization of protein interaction: Phosphorylation of Ser172 specifically destabilizes the interaction between TAL1 and LSD1. In vitro phosphorylation assays demonstrated that phosphorylated TAL1 completely lost its ability to interact with purified LSD1, while the S172A mutant (which cannot be phosphorylated at this site) maintained this interaction regardless of PKA treatment .

• Epigenetic effects: The dissociation of LSD1 from TAL1 leads to promoter H3K4 hypermethylation, as LSD1 normally functions to remove methyl groups from methylated lysine 4 on histone H3 tails. This hypermethylation results in activation of target genes that would otherwise be suppressed .

• Cellular differentiation impact: In murine erythroleukemia (MEL) cells, the TAL1 S172A mutant (which enhances interaction with LSD1) inhibited DMSO-induced erythroid differentiation, while deletion of the LSD1 interacting domain significantly promoted differentiation. This indicates that the phosphorylation state of Ser172, by controlling the TAL1-LSD1 interaction, plays a crucial role in regulating erythroid differentiation .

• T-ALL implications: Knockdown of TAL1 or LSD1 in T-ALL Jurkat cells led to derepression of TAL1 target genes, accompanied by elevated promoter H3K4 methylation, suggesting that the TAL1-LSD1 interaction (regulated by Ser172 phosphorylation) has important implications for leukemogenesis .

What is the role of Akt-mediated phosphorylation of TAL1 at Thr90 in gene regulation and cellular function?

Akt-mediated phosphorylation of TAL1 at Thr90 plays distinct regulatory roles:

• Decreased repressor activity: Phosphorylation of Thr90 by Akt decreases the repressor activity of TAL1 on specific promoters, such as the EpB42 (P4.2) promoter, as demonstrated through luciferase assays .

• Nuclear redistribution: This phosphorylation causes redistribution of TAL1 within the nucleus, potentially affecting its access to target genes and interaction with other transcriptional regulators .

• PI3K dependency: The phosphorylation occurs in a phosphatidylinositol 3-kinase (PI3K)-dependent manner, linking TAL1 regulation to this important signaling pathway .

• Physical interaction: Coimmunoprecipitation experiments revealed that TAL1 is present in Akt immune complexes, suggesting a physical interaction between these proteins that facilitates the phosphorylation event .

How do the short and long isoforms of TAL1 differ in their phosphorylation patterns and functional outcomes?

The short and long isoforms of TAL1 exhibit distinct patterns of phosphorylation and functional outcomes:

• Differential DNA binding: TAL1-short binds more strongly to TAL1 E-protein partners and functions as a stronger transcription factor than TAL1-long. ChIP-seq and RNA-seq analyses identified a similar number of targets for TAL1-short (2,043) as previously identified for both isoforms combined (1,696), while only 120 targets were attributed specifically to TAL1-long .

• Unique transcriptional signatures: TAL1-short has a unique transcriptional signature that promotes apoptosis, whereas TAL1-long appears to be involved in T-cell activation and proliferation. This fundamental difference is evidenced by gene set enrichment analysis showing that TAL1-short targets were enriched for genes involved in apoptosis .

• Hematopoietic effects: In mouse bone marrow studies, overexpression of both isoforms prevented lymphoid differentiation, but TAL1-short alone led to hematopoietic stem cell exhaustion. Additionally, TAL1-short promoted erythropoiesis and reduced cell survival in the CML cell line K562 .

• Therapeutic implications: While TAL1 and its partners are considered promising therapeutic targets in T-ALL treatment, research suggests that TAL1-short could act as a tumor suppressor, indicating that altering the ratio of TAL1 isoforms might be a preferred therapeutic approach rather than targeting TAL1 activity as a whole .

The search results don't explicitly address differential phosphorylation patterns between the isoforms, but the functional differences suggest that phosphorylation may affect each isoform differently or that the isoforms may be preferentially phosphorylated at different sites.

What experimental approaches can differentiate between phosphorylation events on different TAL1 isoforms?

To differentiate phosphorylation events between TAL1 isoforms, researchers can employ several specialized approaches:

• Isoform-specific expression systems: As demonstrated in the search results, researchers can silence endogenous TAL1 (e.g., using shRNA targeting the 3' UTR) and then express each isoform separately to study their phosphorylation patterns and functional consequences .

• Mass spectrometry analysis: Though not explicitly mentioned in the search results, quantitative phosphoproteomic analysis can identify and compare phosphorylation sites between isoforms when they are separately expressed.

• Isoform-specific antibodies: Developing antibodies that can distinguish between the isoforms, allowing for selective immunoprecipitation and subsequent phosphorylation analysis.

• Functional assays with phosphorylation site mutants: Creating phosphorylation site mutants (e.g., S172A) in both TAL1-short and TAL1-long backgrounds to assess how the same phosphorylation event might differently affect each isoform .

• Chromatin analysis: As demonstrated in the search results, the isoforms appear to interact differently with chromatin. Techniques like ChIP-seq following phosphorylation-inducing treatments can reveal how phosphorylation affects chromatin binding by each isoform .

What are common technical challenges in detecting phosphorylated TAL1 and how can they be addressed?

Common technical challenges in phospho-TAL1 detection include:

• Antibody specificity: Ensuring antibodies are truly specific for phosphorylated forms of TAL1 at particular residues. This can be addressed by using phosphorylation site mutants (S172A, T90A) as negative controls and by validating antibodies with in vitro phosphorylated recombinant proteins .

• Low abundance: Phosphorylated forms may represent only a small fraction of total TAL1. Researchers can address this by using phospho-enrichment methods prior to detection or by using more sensitive detection systems like AlphaLISA technology (similar to that described for TFEB) .

• Temporal dynamics: Phosphorylation events are often transient. Time-course experiments with tight intervals can help capture these events.

• Complex isoform patterns: As demonstrated in the search results, TAL1 has complex expression patterns with multiple isoforms generated through different promoters and alternative splicing . Researchers should design detection strategies that can distinguish between these patterns.

• Context-dependent regulation: The search results show that phosphorylation of TAL1 and its effects can be highly context-dependent, varying between cell types and developmental stages . Researchers should carefully select appropriate cellular models and validate findings across multiple systems.

How can researchers validate the specificity of antibodies for phosphorylated TAL1?

To validate the specificity of phospho-TAL1 antibodies, researchers should:

• Use phosphorylation site mutants: Create and express TAL1 mutants where the phosphorylation site of interest is replaced with a non-phosphorylatable residue (e.g., S172A for serine 172). A legitimate phospho-specific antibody should not detect these mutants under conditions that induce phosphorylation in wild-type TAL1 .

• Employ kinase treatments: Treat recombinant TAL1 with or without the relevant kinase (e.g., PKA for Ser172, Akt for Thr90) in vitro and confirm that the antibody only detects the kinase-treated sample .

• Utilize phosphatase treatments: Treat samples with phosphatases to remove phosphorylation and confirm loss of antibody detection.

• Perform peptide competition assays: Challenge antibody detection with phosphorylated and non-phosphorylated peptides containing the sequence surrounding the phosphorylation site.

• Cross-validate with multiple detection methods: For example, complement phospho-specific antibody detection with mass spectrometry or phospho-amino acid analysis to confirm the presence and identity of the phosphorylated residue.

How does TAL1 phosphorylation contribute to leukemogenesis, particularly in T-ALL?

TAL1 phosphorylation contributes to leukemogenesis in T-ALL through several mechanisms:

• Altered transcriptional repression: The search results indicate that phosphorylation of TAL1 at different sites can modulate its repressor function. For example, Akt-mediated phosphorylation at Thr90 decreased TAL1's repressor activity on the EpB42 promoter . In T-ALL, dysregulation of this phosphorylation could contribute to abnormal gene expression patterns.

• Disrupted interactions with coregulators: Phosphorylation of Ser172 specifically destabilizes the interaction between TAL1 and LSD1, a histone demethylase. In T-ALL Jurkat cells, knockdown of either TAL1 or LSD1 led to derepression of TAL1 target genes, accompanied by elevated promoter H3K4 methylation. This suggests that the TAL1-LSD1 interaction, which is regulated by phosphorylation, plays an important role in maintaining the leukemic state .

• Isoform-specific effects: Research has shown that TAL1 isoforms have distinct functional profiles. While both isoforms can prevent lymphoid differentiation when overexpressed, TAL1-short uniquely promotes apoptosis and may act as a tumor suppressor. The ratio between these isoforms, potentially influenced by phosphorylation, could be critical in leukemia development and progression .

• Signaling pathway integration: The phosphorylation of TAL1 by Akt connects TAL1 activity to the PI3K/Akt pathway, a key signaling cascade often dysregulated in cancer. This integration allows environmental and cellular signals to modulate TAL1 function through phosphorylation events .

What therapeutic strategies could target TAL1 phosphorylation in hematological malignancies?

Several therapeutic strategies could target TAL1 phosphorylation in hematological malignancies:

• Isoform ratio modulation: Research suggests that altering the ratio of TAL1 isoforms could be a preferred therapeutic approach. Specifically, increasing the relative abundance of TAL1-short, which promotes apoptosis and may act as a tumor suppressor, could counteract the oncogenic effects of TAL1 dysregulation .

• Kinase inhibition: Targeting the kinases responsible for TAL1 phosphorylation (e.g., PKA for Ser172, Akt for Thr90) could modulate TAL1 activity. PI3K/Akt pathway inhibitors, many of which are already in clinical development for various cancers, could potentially affect TAL1 phosphorylation at Thr90 .

• Disrupting or enhancing specific protein interactions: Compounds designed to specifically disrupt the interaction between TAL1 and LSD1 might mimic the effect of Ser172 phosphorylation, potentially promoting differentiation in certain contexts .

• Epigenetic therapy combinations: Since TAL1 phosphorylation affects interactions with epigenetic regulators like LSD1, combination therapies with epigenetic-targeting drugs might be particularly effective .

• Phosphorylation-sensitive degraders: Developing proteolysis-targeting chimeras (PROTACs) or similar technologies that preferentially target phosphorylated or non-phosphorylated forms of TAL1 could allow for selective degradation of oncogenic TAL1 configurations.

What are promising new technologies for studying TAL1 phosphorylation dynamics in real-time?

Several promising technologies could advance real-time studies of TAL1 phosphorylation dynamics:

• Phospho-sensitive fluorescent reporters: Development of genetically encoded biosensors that change fluorescence properties when TAL1 is phosphorylated at specific sites could enable real-time visualization of phosphorylation events in living cells.

• Proximity-based labeling technologies: Methods like BioID or APEX could be used to identify proteins that interact with TAL1 specifically when it is phosphorylated or dephosphorylated at certain residues.

• AlphaLISA and related technologies: As mentioned in the search results for TFEB phosphorylation detection, sandwich immunoassay technologies like AlphaLISA offer quantitative detection of phosphorylated proteins with high sensitivity, potentially enabling real-time measurement of phosphorylation dynamics in cell-based assays .

• Mass spectrometry with stable isotope labeling: Techniques like SILAC (Stable Isotope Labeling with Amino acids in Cell culture) combined with time-course experiments could provide quantitative temporal profiles of multiple phosphorylation events on TAL1 simultaneously.

• Single-cell phosphoproteomic approaches: Emerging technologies for analyzing phosphorylation at the single-cell level could reveal heterogeneity in TAL1 phosphorylation states within populations of cells, potentially uncovering subpopulations with distinct regulatory patterns.

How might integrated multi-omics approaches advance our understanding of TAL1 phosphorylation networks?

Integrated multi-omics approaches could significantly advance understanding of TAL1 phosphorylation networks by:

• Connecting phosphorylation to transcriptional outputs: As demonstrated in the search results, researchers have already begun to integrate ChIP-seq and RNA-seq data to identify isoform-specific transcriptional targets. Expanding this to include phosphoproteomics could reveal how specific phosphorylation events influence target gene selection and regulation .

• Revealing signaling network context: Integrating phosphoproteomics with other proteomic approaches could place TAL1 phosphorylation within broader signaling networks, identifying upstream regulators and downstream effectors.

• Correlating with chromatin states: The search results indicate that TAL1 phosphorylation affects interactions with epigenetic regulators like LSD1, influencing histone modifications. Integrating phosphoproteomics with epigenomic approaches (ChIP-seq, ATAC-seq) could map how phosphorylation states correlate with chromatin accessibility and histone modifications at target genes .

• Capturing temporal dynamics: Multi-omics approaches with temporal resolution could reveal the sequence of events following TAL1 phosphorylation, from immediate protein interaction changes to subsequent chromatin remodeling and transcriptional reprogramming.

• Identifying disease-specific networks: Applying these integrated approaches across normal hematopoietic cells and leukemic samples could identify disease-specific alterations in TAL1 phosphorylation networks, potentially revealing new therapeutic vulnerabilities.